Deciphera Pharmaceuticals (DCPH) Tops Q3 EPS by 17c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2020 Financial Results
November 5, 2020 4:01 PM ESTU.S. QINLOCK® Net Revenue of $14.7 Million in the First Full Quarter of Launch
Marketing Authorisation Application for QINLOCK in Fourth-line GIST Validated by the European Medicines Agency; Commercial Planning for Europe Underway
Enrollment for QINLOCK Phase 3 INTRIGUE Study Expected to be Completed in Fourth Quarter 2020
DCC-3014 Phase 1 Study Results in Additional TGCT Patients to be Featured in an Oral Presentation at the CTOS 2020 Virtual Annual Meeting
Company to Host Conference Call Today at 4:30 PM ET
WALTHAM, Mass.--(BUSINESS... More
